Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for GlioblastomaGangadhara R. Sareddy, Ratna K. Vadlamudi|Scientific Reports|2016Cited by 71
Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancerJinyou Liu, Gangadhara R. Sareddy|Oncotarget|2017Cited by 43
KDM1A inhibition augments the efficacy of rapamycin for the treatment of endometrial cancerPrabhakar Pitta Venkata, Gangadhara R. Sareddy|Cancer Letters|2021Cited by 19
Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancerPrabhakar Pitta Venkata, Gangadhara R. Sareddy|Cancer Letters|2023Cited by 18
Reticulocalbin 3 Is a Novel Mediator of Glioblastoma ProgressionYi He, Gangadhara R. Sareddy|Cancers|2023Cited by 5